share_log

HC Wainwright & Co. Maintains Buy on First Wave BioPharma, Lowers Price Target to $4

Benzinga Real-time News ·  Dec 2, 2022 05:08

HC Wainwright & Co. analyst Yi Chen maintains First Wave BioPharma (NASDAQ:FWBI) with a Buy and lowers the price target from $8 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment